Compare Manhattan Associates Inc (MANH) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Revvity Inc — how do they compare? Manhattan Associates Inc trades at $204.05 (market cap $12.06B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Revvity Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Manhattan Associates Inc for 12 Days and Revvity Inc for 12 Days on average.
| MANH | RVTY | |
|---|---|---|
Market Cap | $12.06B | $16.98B |
Volume | 376,150 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $223.76 | $157.36 |
52-Week Low | $120.88 | $82.26 |
Typical Hold Time | 12 Days | 12 Days |
Enterprise Value | $11.93B | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MANH trades at $205.29, up 1.57% with strong technical momentum and bullish moving average signals. The company demonstrates robust profitability with 18.67% net margins and consistent earnings beats, though valuation metrics remain elevated. Recent news includes product expansion with Editions launch and ongoing legal investigations regarding fiduciary duties.
Outlook remains positive with analyst consensus at Buy and $210.50 target, though risks include high valuation multiples and legal scrutiny. The stock offers growth potential through strong operational performance but faces headwinds from potential governance concerns and competitive pressures in the software sector.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
